BioSpace News Archive

180 Life Sciences Corp. announces that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for a follow up scientific advice meeting where the Company will seek guidance on a plan to obtain Conditional Marketing Authorization (CMA) for the use of adalimumab in the treatment of early stage Dupuytren’s disease.

CNS Pharmaceuticals today provided a clinical update for its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer.

AngioDynamics, Inc. announced the completion of enrollment and final treatment in its Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population.

CNS Pharmaceuticals, Inc. today announced that John Climaco, CEO of CNS Pharmaceuticals will participate in a fireside chat at Benzinga’s Virtual Biotech Conference.

Kindeva Drug Delivery (Kindeva), a premier global drug delivery device contract development and manufacturing organization (CDMO), announced that the company has received a grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF), unlocking a £33 million investment with Kindeva toward enhancing inhaler manufacturing and sustainability.

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics for the treatment of solid tumors, announced that the Company’s management will participate in two upcoming investor conferences, to be held in August 2023.